{"url_path":"/sec/bmrn/8-k/2026-04-27/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-04-27","source_url":"https://www.sec.gov/Archives/edgar/data/1048477/0001193125-26-179243-index.html","accession_number":"0001193125-26-179243","cik":"0001048477","ticker":"BMRN","issuer_name":"BIOMARIN PHARMACEUTICAL INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1048477/0001193125-26-179243-index.html","primary_entity_key":"0001048477","primary_entity_name":"BIOMARIN PHARMACEUTICAL INC"},"word_count":133,"has_tables":true,"body_markdown":"Item 7.01\n\nRegulation FD Disclosure.\n\nOn April 27, 2026, BioMarin issued a press release announcing the completion of the previously announced Merger. A copy of the press release is attached as Exhibit 99.1 hereto and is incorporated herein by reference.\n\nThe information contained in this Item 7.01 and Exhibit 99.1 attached hereto is furnished pursuant to Item 7.01 of Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by BioMarin regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing."}